Related Experiment Videos
Antiarrhythmic treatment of atrial arrhythmias
1Service de Cardiologie, C.H.U.-Sart Tilman, Université de Liège, Belgium.
Insights
Atrial premature beats rarely need treatment beyond lifestyle changes. Acute atrial fibrillation management varies from electrical cardioversion to medications like digitalis, beta-blockers, or amiodarone, depending on patient stability and arrhythmia type.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial arrhythmias, including premature beats and atrial fibrillation, are common and require tailored management strategies.
- Current treatment guidelines emphasize a stepwise approach based on acute versus chronic presentation and hemodynamic stability.
Purpose of the Study:
- To outline the therapeutic strategies for managing atrial premature beats and atrial fibrillation.
- To differentiate treatment approaches for acute and chronic atrial fibrillation, including pharmacological and interventional options.
Main Methods:
- Review of established treatment protocols for atrial arrhythmias.
- Discussion of pharmacological agents including digitalis, beta-blockers, class I antiarrhythmics, and amiodarone.
- Consideration of electrical cardioversion and catheter ablation for refractory cases.
Main Results:
- Atrial premature beats typically require only reassurance and lifestyle modification.
- Acute atrial fibrillation management depends on hemodynamic stability, with electrical cardioversion for decompensation and pharmacological options for stable patients.
- Long-term management of atrial fibrillation involves combination therapy to prevent recurrences or control ventricular rate, with amiodarone and beta-blockers being highly effective. Catheter ablation is an option for refractory cases.
Conclusions:
- A nuanced approach is essential for managing atrial arrhythmias, balancing efficacy with patient-specific factors.
- Pharmacological and interventional therapies offer effective solutions for acute and chronic atrial fibrillation, aiming to restore sinus rhythm or control ventricular rate.
Abstract:
Atrial premature beats seldom require an antiarrhythmic treatment; reassurance and suppression of coffee, alcohol, and tobacco generally suffice. Acute atrial fibrillation is best treated by electrical cardioversion if it induces acute cardiovascular decompensation. If it is not poorly tolerated, the arrhythmia may be treated with digitalis at doses sufficient to keep the ventricular response rate at 70-90/min. This therapy may restore sinus rhythm, but conversion to sinus rhythm often requires the combined use of digitalis with a beta-blocker or class I antiarrhythmic drug (quinidine, disopyramide, procainamide, propafenone, or flecainide). Digitalis must be avoided in the presence of a preexcitation, and class IA agents, which facilitate atrioventricular (AV) nodal transport, must never be used without digitalis. Chemical cardioversion may also be achieved by i.v. amiodarone. Long-term prevention of recurrences after cardioversion or in the presence of recurrent paroxysmal atrial fibrillation requires digitalis combined with a class I agent, or a beta-blocker, preferably sotalol. Amiodarone is also very efficacious. Special mention should be made of atrial fibrillations of vagal or sympathetic origin, which are best treated by amiodarone, or beta-blockade (nadolol), respectively. In the presence of chronic established atrial fibrillation, digitalis in combination with a beta-blocking agent or a calcium antagonist, such as verapamil or diltiazem, may be useful to slow the ventricular response rate. If successful control cannot be obtained, catheter ablation of the AV node with implantation of a rate-responsive pacemaker must be contemplated. The therapeutic approach in patients with chronic atrial fibrillation, whether or not associated, is similar to atrial flutter.(ABSTRACT TRUNCATED AT 250 WORDS)